T2DM (TYPE 2 DIABETES MELLITUS)
Clinical trials for T2DM (TYPE 2 DIABETES MELLITUS) explained in plain language.
Never miss a new study
Get alerted when new T2DM (TYPE 2 DIABETES MELLITUS) trials appear
Sign up with your email to follow new studies for T2DM (TYPE 2 DIABETES MELLITUS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a diabetes pill protect kidneys? major trial launches
Disease control Not yet recruitingThis study tests whether adding ganagliflozin tablets to standard treatment can slow the worsening of kidney disease in people with type 2 diabetes. About 1,244 adults with both conditions will be randomly assigned to receive either the drug or a placebo for 120 weeks. The main g…
Matched conditions: T2DM (TYPE 2 DIABETES MELLITUS)
Phase: PHASE4 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
New Once-Daily combo pill aims to simplify diabetes care in china
Disease control Not yet recruitingThis study tests a new once-daily pill that combines three diabetes drugs (henagliflozin, retagliptin, and metformin) in 300 Chinese adults with type 2 diabetes. The goal is to see if it safely improves blood sugar control over 24 weeks. Participants include newly diagnosed patie…
Matched conditions: T2DM (TYPE 2 DIABETES MELLITUS)
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New triple therapy aims to shield kidneys in diabetes patients
Disease control Not yet recruitingThis study looks at whether adding a third drug (dulaglutide) to two existing medications can better protect the kidneys of Chinese adults with type 2 diabetes and mild-to-moderate chronic kidney disease. About 468 participants who are already on two kidney-protecting drugs will …
Matched conditions: T2DM (TYPE 2 DIABETES MELLITUS)
Phase: PHASE4 • Sponsor: First Affiliated Hospital of Wannan Medical College • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Shocking diabetes treatment? new procedure aims to reset the gut
Disease control Not yet recruitingThis study tests a procedure called ReCET that uses mild electrical pulses to treat the lining of the small intestine. It aims to improve blood sugar control and reduce fat in the liver for people with type 2 diabetes and fatty liver disease who haven't had success with standard …
Matched conditions: T2DM (TYPE 2 DIABETES MELLITUS)
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New drug combo aims to reverse fatty liver damage in diabetics
Disease control Not yet recruitingThis study tests whether a drug called chiglitazar, combined with anti-inflammatory and liver-protecting treatments, can help people with both type 2 diabetes and a serious fatty liver disease called MASH. About 300 adults will receive either the combination or a placebo to see i…
Matched conditions: T2DM (TYPE 2 DIABETES MELLITUS)
Phase: PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New diabetes combo pill put to the test in healthy volunteers
Knowledge-focused Not yet recruitingThis study checks if a new tablet that combines two diabetes medicines (Chiglitazar and Metformin) works the same as taking them separately. It involves 24 healthy adults who take a single dose of each version under fed conditions. The goal is to measure how the drug moves throug…
Matched conditions: T2DM (TYPE 2 DIABETES MELLITUS)
Phase: NA • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Knowledge-focused
Last updated May 26, 2026 05:02 UTC
-
New diabetes combo pill put to the test in healthy volunteers
Knowledge-focused Not yet recruitingThis study checks if a new tablet that combines two diabetes drugs (chiglitazar and metformin) works the same as the standard separate pills. It involves 64 healthy adults aged 18-45 who take a single dose of each version under fed conditions. The goal is to compare how the body …
Matched conditions: T2DM (TYPE 2 DIABETES MELLITUS)
Phase: NA • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Knowledge-focused
Last updated May 22, 2026 14:02 UTC
-
New diabetes combo pill tested in healthy volunteers
Knowledge-focused Not yet recruitingThis early-stage study tests a new extended-release tablet that combines two diabetes drugs (Chiglitazar and Metformin) in 28 healthy Chinese adults. The goal is to see how a high-fat meal changes drug levels and how the body processes the drug after multiple doses. Participants …
Matched conditions: T2DM (TYPE 2 DIABETES MELLITUS)
Phase: PHASE1 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Knowledge-focused
Last updated May 20, 2026 11:57 UTC